New adaptive radiation trial aims to cut prostate cancer treatment time without sacrificing quality of life
NCT ID NCT06355050
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new type of radiation therapy for early-stage prostate cancer that delivers very high doses in just a few sessions. The radiation machine adjusts the beam daily based on the patient's anatomy, aiming to protect healthy tissue. Researchers will track quality of life and side effects in 150 patients across Germany and compare them to standard radiation approaches.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ultrahypofractionated adaptive radiation therapy (Varian Ethos device)
What this could lead to
If successful, this could offer a shorter, more precise radiation treatment for early prostate cancer with fewer side effects and better quality of life.
What could go wrong
This is an early-phase observational study with no control group, so results may not prove superiority over standard radiation. Side effects from high-dose radiation remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Radiotherapy and Radiation Oncology, Jena University Hospital
RECRUITINGJena, Germany
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••